MCID: PTN014
MIFTS: 55

Patent Ductus Arteriosus 1

Categories: Rare diseases, Cardiovascular diseases, Genetic diseases

Aliases & Classifications for Patent Ductus Arteriosus 1

MalaCards integrated aliases for Patent Ductus Arteriosus 1:

Name: Patent Ductus Arteriosus 1 57 29
Patent Ductus Arteriosus 57 12 76 53 37 13 6 15 63
Ductus Arteriosus, Patent 12 44
Pda1 57 53
Pda 57 53
Patent Ductus Arteriosus, Susceptibility to 57
Patent Ductus Arteriosus - Persisting Type 73
Patent Ductus Arteriosus Familial 53
Patency of the Ductus Arteriosus 53
Ductus Arteriosus Patent 55
Patent Ductus Botalli 12

Characteristics:

OMIM:

57
Inheritance:
autosomal recessive


HPO:

32
patent ductus arteriosus 1:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 57 607411
Disease Ontology 12 DOID:13832
ICD10 33 Q25.0
ICD9CM 35 747.0
MeSH 44 D004374
NCIt 50 C84492
SNOMED-CT 68 156928009 83330001
MedGen 42 C4282128
KEGG 37 H01630
SNOMED-CT via HPO 69 258211005

Summaries for Patent Ductus Arteriosus 1

OMIM : 57 Persistent patency of the ductus arteriosus, or patent ductus arteriosus (PDA), is the second most common congenital heart disease, affecting approximately 1 in 1,600 to 5,000 live births in the U.S. (Mitchell et al., 1971). In fetal life, the ductus arteriosus, a muscular artery, shunts blood from the pulmonary artery to the aorta, bypassing the lungs. Its abrupt closure at birth establishes the mature circulatory pattern and represents a dramatic example of vascular remodeling. Failure of this normal process results in persistent PDA, which left untreated can result in pulmonary hypertension and heart failure. Closure of the ductus is a complex process. Aspects of this process are regulated by oxygen tension and a decrease in levels of hormones such as prostaglandin E2. PDA occurring in preterm infants often closes spontaneously or in response to inhibitors of prostaglandin biosynthesis (Ramsay et al., 1987). Term PDA typically has not been regarded as a genetic disorder, because it most often occurs sporadically. Nonetheless, term PDA recurs among 5% of sibs of PDA cases (Polani and Campbell, 1960; Lamy et al., 1957), suggesting a genetic component to disease pathogenesis that has typically been presumed to be multifactorial. That single genes can influence this trait has been demonstrated by a mouse model of PDA resulting from disruption of the prostaglandin E2 receptor (Nguyen et al., 1997) and by rare syndromic forms of PDA such as Char syndrome (169100), an autosomal dominant disorder caused by mutations in the transcription factor TFAP2B (601601) (Mani et al., 2002). (607411)

MalaCards based summary : Patent Ductus Arteriosus 1, also known as patent ductus arteriosus, is related to patent ductus arteriosus 2 and patent ductus arteriosus 3. An important gene associated with Patent Ductus Arteriosus 1 is PTPN11 (Protein Tyrosine Phosphatase, Non-Receptor Type 11), and among its related pathways/superpathways are Vascular smooth muscle contraction and Heart Development. The drugs Acetaminophen and Ibuprofen have been mentioned in the context of this disorder. Affiliated tissues include heart, lung and brain, and related phenotypes are patent ductus arteriosus and cardiovascular system

PubMed Health : 63 About patent ductus arteriosus: Patent ductus arteriosus (PDA) is a heart problem that affects some babies soon after birth. In PDA, abnormal blood flow occurs between two of the major arteries connected to the heart. These arteries are the aorta and the pulmonary (PULL-mun-ary) artery.Before birth, these arteries are connected by a blood vessel called the ductus arteriosus. This blood vessel is a vital part of fetal blood circulation.Within minutes or up to a few days after birth, the ductus arteriosus closes. This change is normal in newborns.In some babies, however, the ductus arteriosus remains open (patent). The opening allows oxygen-rich blood from the aorta to mix with oxygen-poor blood from the pulmonary artery. This can strain the heart and increase blood pressure in the lung arteries.

Wikipedia : 76 Patent ductus arteriosus (PDA) is a condition wherein the ductus arteriosus fails to close after... more...

Related Diseases for Patent Ductus Arteriosus 1

Diseases in the Patent Ductus Arteriosus 1 family:

Patent Ductus Arteriosus 2 Patent Ductus Arteriosus 3

Diseases related to Patent Ductus Arteriosus 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 33)
# Related Disease Score Top Affiliating Genes
1 patent ductus arteriosus 2 10.9
2 patent ductus arteriosus 3 10.9
3 familial patent arterial duct 10.7 PRDM6 TFAP2B
4 pulmonary valve insufficiency 10.5 NKX2-6 NPPB
5 tricuspid valve insufficiency 10.5 CRELD1 NPPB PTPN11
6 tricuspid atresia 10.5 CRELD1 GDF1 NKX2-6
7 total anomalous pulmonary venous return 1 10.5 CRELD1 GDF1 NKX2-6
8 complete atrioventricular canal-tetralogy of fallot syndrome 10.5 CRELD1 GATA4
9 complete atrioventricular canal-left heart obstruction syndrome 10.4 CRELD1 GATA4
10 dextro-looped transposition of the great arteries 10.4 GDF1 NKX2-6
11 pulmonary valve stenosis 10.3 GATA4 NKX2-6 PTPN11
12 char syndrome 10.3 ACTA2 TFAP2A TFAP2B
13 aortic aneurysm, familial thoracic 6 10.3 ACTA2 MYH11
14 conotruncal heart malformations 10.2 GATA6 GDF1 NKX2-6
15 partial atrioventricular canal 10.2 CRELD1 GATA4 GATA6
16 complete atrioventricular canal-ventricle hypoplasia syndrome 10.2 CRELD1 GATA4 GATA6
17 hand-foot-genital syndrome 10.1
18 palatopharyngeal incompetence 10.1
19 exencephaly 10.0 TFAP2A TFAP2B
20 pulmonary hypertension 10.0
21 transposition of the great arteries 10.0
22 tricuspid valve disease 9.9 CRELD1 GATA6 GDF1 NKX2-6 NPPB
23 atrial septal defect 4 9.9 GATA4 GATA6 PTPN11 TLL1
24 ebstein anomaly 9.9 CRELD1 GATA4 GDF1 NKX2-6 NPPB
25 pulmonary valve disease 9.8 CRELD1 GATA4 GATA6 NKX2-6 PTPN11
26 familial atrial fibrillation 9.7 GATA4 GATA6 NKX2-6
27 ventricular septal defect 9.7 GATA4 GATA6 GDF1 NKX2-6 NPPB
28 atrioventricular septal defect 9.7 CRELD1 GATA4 GATA6 GDF1 NKX2-6
29 double outlet right ventricle 9.7 CRELD1 GATA4 GATA6 GDF1 NKX2-6
30 atrial heart septal defect 9.3 CRELD1 GATA4 GATA6 GDF1 NKX2-6 TLL1
31 tetralogy of fallot 9.2 CRELD1 GATA4 GATA6 GDF1 NKX2-6 NPPB
32 heart disease 9.2 CRELD1 GATA4 GATA6 GDF1 NKX2-6 NPPB
33 heart septal defect 9.1 ADO CRELD1 GATA4 GATA6 GDF1 NKX2-6

Graphical network of the top 20 diseases related to Patent Ductus Arteriosus 1:



Diseases related to Patent Ductus Arteriosus 1

Symptoms & Phenotypes for Patent Ductus Arteriosus 1

Symptoms via clinical synopsis from OMIM:

57
Cardiovascular Vascular:
patent ductus arteriosus


Clinical features from OMIM:

607411

Human phenotypes related to Patent Ductus Arteriosus 1:

32
# Description HPO Frequency HPO Source Accession
1 patent ductus arteriosus 32 HP:0001643

MGI Mouse Phenotypes related to Patent Ductus Arteriosus 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.25 TLL1 ACTA2 CRELD1 GATA4 GATA6 GDF1
2 cellular MP:0005384 10.1 GATA6 GDF1 MYH11 NKX2-6 PTGER4 PTPN11
3 embryo MP:0005380 9.97 GDF1 NKX2-6 PRDM6 PTPN11 TFAP2A CRELD1
4 mortality/aging MP:0010768 9.93 GATA6 GDF1 MYH11 NKX2-6 PRDM6 PTGER4
5 integument MP:0010771 9.92 GATA4 MYH11 PRDM6 PTGER4 PTPN11 TFAP2A
6 limbs/digits/tail MP:0005371 9.8 ELMOD2 GATA4 GATA6 PTPN11 TFAP2A TFAP2B
7 muscle MP:0005369 9.56 ACTA2 GATA4 GATA6 MYH11 PTGER4 PTPN11
8 respiratory system MP:0005388 9.32 GATA4 GATA6 GDF1 MYH11 NKX2-6 PRDM6

Drugs & Therapeutics for Patent Ductus Arteriosus 1

PubMedHealth treatment related to Patent Ductus Arteriosus 1: 63

Patent ductus arteriosus (PDA) is treated with medicines, catheter-based procedures, and surgery. The goal of treatment is to close the PDA. Closure will help prevent complications and reverse the effects of increased blood volume.Small PDAs often close without treatment. For full-term infants, treatment is needed if the PDA is large or causing health problems. For premature infants, treatment is needed if the PDA is causing breathing problems or heart problems.Talk with your child's doctor about treatment options and how your family prefers to handle treatment decisions.

Drugs for Patent Ductus Arteriosus 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 103-90-2 1983
2
Ibuprofen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15687-27-1 3672
3 Poractant alfa Approved Phase 4,Phase 3,Not Applicable 129069-19-8
4
Indomethacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-86-1 3715
5
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
6
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
7
Iodine Approved, Investigational Phase 4 7553-56-2 807
8 Beractant Approved Phase 4,Not Applicable 108778-82-1
9
Glucosamine Approved, Investigational, Nutraceutical Phase 4 3416-24-8 439213
10 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Antipyretics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Pulmonary Surfactants Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
19 Anti-Infective Agents Phase 4,Phase 3
20 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3
21 Respiratory System Agents Phase 4,Phase 3,Phase 2,Not Applicable
22 Tocolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
23 Antifungal Agents Phase 4
24 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
25 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
26 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
28 Steroid Synthesis Inhibitors Phase 4
29 Anti-Infective Agents, Local Phase 4
30 cadexomer iodine Phase 4
31 Micronutrients Phase 4,Phase 3
32 Trace Elements Phase 4,Phase 3
33 Anticoagulants Phase 4
34 Antimetabolites Phase 4
35 Fibrinolytic Agents Phase 4
36 Glucuronyl glucosamine glycan sulfate Phase 4
37 Hypoglycemic Agents Phase 4
38 Hypolipidemic Agents Phase 4
39 Lipid Regulating Agents Phase 4
40
Clarithromycin Approved Phase 3 81103-11-9 84029
41
Benzocaine Approved, Investigational Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
42
Dexmedetomidine Approved, Vet_approved Phase 3 113775-47-6 68602 5311068
43
Dopamine Approved Phase 2, Phase 3,Not Applicable 51-61-6, 62-31-7 681
44
Nitric Oxide Approved Phase 3,Not Applicable 10102-43-9 145068 160954
45
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782
46
Azithromycin Approved Phase 3,Phase 2 83905-01-5 55185 447043
47
Fenoldopam Approved Phase 2, Phase 3 67227-56-9, 67227-57-0 3341
48
Bosentan Approved, Investigational Phase 3 147536-97-8 104865
49 tannic acid Approved, Nutraceutical Phase 3,Phase 2,Not Applicable
50
Caffeine Approved, Nutraceutical Phase 3 58-08-2 2519

Interventional clinical trials:

(show top 50) (show all 174)
# Name Status NCT ID Phase Drugs
1 Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants Unknown status NCT01544972 Phase 4 Oral paracetamol;Oral ibuprofen
2 Early CPAP in Respiratory Distress Syndrome Unknown status NCT00368680 Phase 4
3 Cpap at Delivery Room for Preterm Infants Unknown status NCT01024361 Phase 4
4 Oral Paracetamol Versus Oral Ibuprofen in Management of Patent Ductus Arteriosus in Preterm Infants: A Randomised Controlled Trial Completed NCT01536158 Phase 4 Oral paracetamol;Oral ibuprofen
5 Comparative Study of Efficacy and Safety of Oral Ibuprofen and Intravenous Ibuprofen in Closure of Patent Ductus Arteriosus in Very Low Birth Weight Infants Completed NCT00642330 Phase 4 oral ibuprofen;intravenous ibuprofen
6 Ibuprofen and Renal Function in Premature Infants Completed NCT00217191 Phase 4 Ibuprofen
7 Safety of Fluconazole Treatment of Premature and Full-term Newborn Infants Completed NCT02079298 Phase 4 Treatment with fluconazole.;2. Treatment with both fluconazole and Ibuprofen.;3. Treatment with ibuprofen.
8 A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years Completed NCT00638092 Phase 4 sodium iodide;Sodium Chloride
9 OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP Recruiting NCT02140580 Phase 4
10 TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence Recruiting NCT02621645 Phase 4
11 Paracetamol Versus Ibuprofen for PDA Closure Active, not recruiting NCT03265782 Phase 4 ibuprofen;paracetamol
12 Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates Terminated NCT00961753 Phase 4 optimized ibuprofen;Standard Ibuprofen
13 Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants Terminated NCT00767039 Phase 4 Survanta (beractant);Curosurf (poractant)
14 Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus in Very Premature Babies Withdrawn NCT00470743 Phase 4 Ibuprofen;Indomethacin
15 L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Hypothyroxinemia Unknown status NCT01306227 Phase 3 L-Thyroxine;water
16 Clarithromycin Prophylaxis in Preterm Infants Colonisation With Ureaplasma Urealyticum and Mycoplasma Hominis Unknown status NCT01652118 Phase 3 clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia;Saline
17 Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus Completed NCT01593163 Phase 3 Ibuprofen EchoG;Standard ibuprofen treatment
18 Platelet Transfusion for Treatment of Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates Completed NCT03022253 Phase 3 Paracetamol;Ibuprofen
19 High-dose Ibuprofen for Patent Ductus Arteriosus (PDA) in Preterm Infant Completed NCT01243996 Phase 2, Phase 3 Ibuprofen
20 Safety and Efficacy Study of Ibuprofen l-Lysine Solution in Premature Infants for Treatment of PDA Completed NCT00440804 Phase 3 ibuprofen l-lysine iv solution (NeoProfen (R) )
21 Ibuprofen vs. Continuous Indomethacin in the Treatment of PDA Completed NCT00485160 Phase 3 Continuous indomethacin;ibuprofen
22 Management of Patent Ductus in Premature Infants Completed NCT00000494 Phase 3 indomethacin
23 Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP) Completed NCT00009646 Phase 3 indomethacin;Indomethacin;Placebo
24 The Pharmacology and Hemodynamics of Dexmedetomidine in Children With Congenital Heart Disease Completed NCT00480740 Phase 3 Dexmedetomidine
25 NIV Strategies for RDS in Preterm Infants. NIV (Non Invasive Ventilation), RDS (Respiratory Distress Syndrome) Completed NCT02259400 Phase 2, Phase 3
26 Canadian Oxygen Trial (COT) Completed NCT00637169 Phase 3
27 Trial of Aggressive Versus Conservative Phototherapy in Infants <1,000 Grams Birth Weight Completed NCT00114543 Phase 3
28 Adding Paracetamol to Ibuprofen for Treatment of Patent Ductus Arteriosus in Preterm Infants Recruiting NCT02002741 Phase 2, Phase 3 Paracetamol;Placebo
29 Acetaminophen vs Indomethacin in Treating hsPDA Recruiting NCT03537144 Phase 3 Indomethacin;Acetaminophen
30 Paracetamol vs Ibuprofen for PDA Closure in Preterm Infants. Recruiting NCT02056223 Phase 2, Phase 3 Intravenous paracetamol;Intravenous ibuprofen
31 Paracetamol (Acetaminophen) for Closure of PDA in Preterm Infants Recruiting NCT01755728 Phase 3 Paracetamol;Ibuprofen
32 Comparison of Two Flow Rates of HHHFNC to Prevent Extubation Failure in Preterm Infants Recruiting NCT02681315 Phase 3
33 Dose Reduction of Antenatal Betamethasone Given to Prevent the Neonatal Complications Associated With Very Preterm Birth Recruiting NCT02897076 Phase 3 betamethasone 24 mg;12mg betamethasone +placebo
34 Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI) Active, not recruiting NCT01630278 Phase 3 Ibuprofen;Placebo
35 Management of the PDA Trial Not yet recruiting NCT03456336 Phase 3
36 Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants Not yet recruiting NCT02620761 Phase 2, Phase 3 Fenoldopam;0.9%NS
37 An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants Terminated NCT00750581 Phase 2, Phase 3 Indomethacin
38 Surfactant Versus Nasal Continuous Positive Airway Pressure (nCPAP) for Respiratory Distress Syndrome in the Newborn ≥ 35 Weeks of Gestation Terminated NCT01306240 Phase 3
39 A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor Terminated NCT02377466 Phase 3 Retosiban IV infusion;Placebo IV infusion
40 Persistent Pulmonary Hypertension of the Newborn Terminated NCT01389856 Phase 3 Bosentan;Matching placebo
41 Inositol to Reduce Retinopathy of Prematurity Terminated NCT01954082 Phase 3 myo-Inositol 5% Injection;Placebo
42 TINN2: Treat Infection in NeoNates 2 Withdrawn NCT02282176 Phase 3 Azithromycin;Placebo
43 The Best Treatment Strategy: Surgical vs Pharmacological to Close the Ductus Arteriosus Persistent in Preterm Infants Unknown status NCT02602054 Phase 2 Control group
44 Treating the Resistant Patent Ductus Arteriosus (PDA) Unknown status NCT00616382 Phase 2 Indomethacin;Pentoxifylline
45 Paracetamol and Patent Ductus Arteriosus (PDA) Unknown status NCT01291654 Phase 2 Paracetamol;NSAID;D5W
46 Comparison of Oral and Intravenous Ibuprofen for PDA Treatment in Premature Infants Unknown status NCT01149564 Phase 1, Phase 2 iv ibuprofen;oral ibuprofen
47 Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants Unknown status NCT00910234 Phase 1, Phase 2 recombinant human erythropoietin (rhEpo);recombinant human erythropoietin (rhEpo);Normal saline
48 Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins Unknown status NCT02230163 Phase 1, Phase 2
49 Indomethacin Versus Placebo in Women With Preterm Premature Rupture of Membranes (PPROM) Unknown status NCT00466128 Phase 2 indomethacin
50 Early FETO for Severe Congenital Diaphragmatic Hernia Unknown status NCT01731509 Phase 2

Search NIH Clinical Center for Patent Ductus Arteriosus 1

Cochrane evidence based reviews: ductus arteriosus, patent

Genetic Tests for Patent Ductus Arteriosus 1

Genetic tests related to Patent Ductus Arteriosus 1:

# Genetic test Affiliating Genes
1 Patent Ductus Arteriosus 1 29

Anatomical Context for Patent Ductus Arteriosus 1

MalaCards organs/tissues related to Patent Ductus Arteriosus 1:

41
Heart, Lung, Brain, Kidney, Smooth Muscle, Bone, Testes

Publications for Patent Ductus Arteriosus 1

Articles related to Patent Ductus Arteriosus 1:

(show top 50) (show all 762)
# Title Authors Year
1
Percutaneous Occlusion of Patent Ductus Arteriosus for an Elderly Patient With Refractory Congestive Heart Failure. ( 29367269 )
2018
2
Incidental finding of pulmonary arterial sling during patent ductus arteriosus surgery in a patient with Mowat-Wilson syndrome. ( 29954473 )
2018
3
Incidental adult polysplenia with situs inversus, interrupted inferior vena cava with azygos continuation, patent ductus arteriosus, and aortic branches variations: a case report. ( 29607204 )
2018
4
Simultaneous transcatheter therapy for perimembranous ventricular septal defect combined with patent ductus arteriosus. ( 28497553 )
2017
5
Comparative Effectiveness of Nonsteroidal Anti-inflammatory Drug Treatment vs No Treatment for Patent Ductus Arteriosus in Preterm Infants. ( 28046188 )
2017
6
Heart rate and blood pressure variations after transvascular patent ductus arteriosus occlusion in dogs. ( 28898782 )
2017
7
Neurodevelopmental Outcome in Relation to Treatment of Patent Ductus Arteriosus-Reply. ( 28846753 )
2017
8
An experimental canine patent ductus arteriosus occlusion device based on shape memory polymer foam in a nitinol cage. ( 28759840 )
2017
9
Patent Ductus Arteriosus in Preterm Infants, Part 1: Understanding the Pathophysiologic Link Between the Patent Ductus Arteriosus and Clinical Complications. ( 28847349 )
2017
10
Efficacy and Safety of Rectal Ibuprofen for Patent Ductus Arteriosus Closure in Very Low Birth Weight Preterm Infants. ( 28052714 )
2017
11
Lung function in very low birth weight infants after pharmacological and surgical treatment of patent ductus arteriosus - a retrospective analysis. ( 28056907 )
2017
12
Neurodevelopmental Outcome in Relation to Treatment of Patent Ductus Arteriosus. ( 28846755 )
2017
13
Neonatal Patent Ductus Arteriosus Ligation Operations Performed by Adult Cardiac Surgeons. ( 28795028 )
2017
14
Echocardiographic assessment of patent ductus arteriosus in very low birthweight infants over time: prospective observational study. ( 28043190 )
2017
15
Outcome after transcatheter occlusion of patent ductus arteriosus in infants less than 6 kg: A national study from United Kingdom and Ireland. ( 28799706 )
2017
16
Percutaneous Patent Ductus Arteriosus (PDA) Closure During Infancy: A Meta-analysis. ( 28087683 )
2017
17
Intraoperative High-Frequency Jet Ventilation Is Equivalent to Conventional Ventilation During Patent Ductus Arteriosus Ligation. ( 28901229 )
2017
18
Paracetamol in Patent Ductus Arteriosus Treatment: Efficacious and Safe? ( 28828381 )
2017
19
Neurodevelopmental Outcome in Relation to Treatment of Patent Ductus Arteriosus. ( 28846759 )
2017
20
Incidence of postoperative implant-related bacterial endocarditis in dogs that underwent trans-catheter embolization of a patent ductus arteriosus without intra- and post-procedural prophylactic antibiotics. ( 28757032 )
2017
21
Transcatheter Occlusion of Patent Ductus Arteriosus in Preterm Infants Weighing Less Than 2 kg With the Amplatzer Duct Occluder II Additional Sizes Device. ( 28916428 )
2017
22
Urinary Neutrophil Gelatinase-associated Lipocalin in the evaluation of Patent Ductus Arteriosus and AKI in Very Preterm Neonates: a cohort study. ( 28068947 )
2017
23
Relationship between Device Size and Body Weight in Dogs with Patent Ductus Arteriosus Undergoing Amplatz Canine Duct Occluder Deployment. ( 28782853 )
2017
24
Transcatheter Closure of Patent Ductus Arteriosus in Children with the Occlutech Duct Occluder. ( 28828684 )
2017
25
Sizing of patent ductus arteriosus in adults for transcatheter closure using the balloon pull-through technique. ( 28944572 )
2017
26
Infections following surgical patent ductus arteriosus ligation in VLBW neonates. ( 28757329 )
2017
27
Anatomic, histopathologic, and echocardiographic features in a dog with an atypical pulmonary valve stenosis with a fibrous band of tissue and a patent ductus arteriosus. ( 28697788 )
2017
28
Tale of Two Patent Ductus Arteriosus Severity Scores: Similarities and Differences. ( 28787748 )
2017
29
Comparison of the Mortality and In-Hospital Outcomes of Preterm Infants Treated with Ibuprofen for Patent Ductus Arteriosus with or without Clinical Symptoms Attributable to the Patent Ductus Arteriosus at the Time of Ibuprofen Treatment. ( 27914140 )
2017
30
Isolated left brachiocephalic artery with the right aortic arch: A rare differential of large patent ductus arteriosus. ( 28163435 )
2017
31
Minimally invasive thoracoscopic closure versus thoracotomy in children with patent ductus arteriosus. ( 27993195 )
2017
32
Initial experience with the 3.3 Fr Mongoose(Ar) pigtail catheter for aortic angiography during patent ductus arteriosus closure in small patients. ( 28928609 )
2017
33
Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. ( 28004188 )
2017
34
Successful Pulmonary Artery Embolization for the Management of Hemoptysis in a Patient with Eisenmenger Syndrome Caused by Patent Ductus Arteriosus. ( 29021475 )
2017
35
Urinary NT-proBNP levels and echocardiographic parameters for patent ductus arteriosus. ( 28906496 )
2017
36
Transcatheter Occlusion of the Patent Ductus Arteriosus in 747 InfantsA &amp;lt;6 kg: Insights From the NCDR IMPACT Registry. ( 28823780 )
2017
37
B-type natriuretic peptide levels normalise in preterm infants without a patent ductus arteriosus by the fifth postnatal day. ( 27206680 )
2016
38
Patent Ductus Arteriosus in the Preterm Infant: An Update on Morbidity and Mortality. ( 27197950 )
2016
39
Cardiac biomarkers and haemodynamically significant patent ductus arteriosus in preterm infants. ( 27998626 )
2016
40
Trends and Variation in Management and Outcomes of Very Low Birth Weight Infants with Patent Ductus Arteriosus. ( 27509008 )
2016
41
A conservative treatment of patent ductus arteriosus in very low birth weight infants. ( 28042972 )
2016
42
Mandatory closure versus nonintervention for patent ductus arteriosus in very preterm infants. ( 27908647 )
2016
43
Adult patent ductus arteriosus : An unusual cause of heart failure in an octogenarian female. ( 27565643 )
2016
44
Editorial: Patent Ductus Arteriosus in Extremely Premature Neonates. ( 27197948 )
2016
45
Genes and patent ductus arteriosus. ( 27568244 )
2016
46
A Hemodynamically Significant Patent Ductus Arteriosus Does Not Affect Cerebral or Renal Tissue Oxygenation in Preterm Infants. ( 27088709 )
2016
47
Short-Term Outcomes of Patent Ductus Arteriosus Closure With New OcclutechAr Duct Occluder: A Multicenter Study. ( 27090770 )
2016
48
Patent ductus arteriosus illuminating an old eponym. ( 27154278 )
2016
49
Comparison of effectiveness and cost of patent ductus arteriosus device occlusion versus surgical ligation of patent ductus arteriosus. ( 27648051 )
2016
50
Near-infrared spectroscopy for detection of a significant patent ductus arteriosus. ( 27603562 )
2016

Variations for Patent Ductus Arteriosus 1

ClinVar genetic disease variations for Patent Ductus Arteriosus 1:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PTPN11 NM_002834.4(PTPN11): c.184T> G (p.Tyr62Asp) single nucleotide variant Pathogenic rs121918460 GRCh37 Chromosome 12, 112888168: 112888168
2 PTPN11 NM_002834.4(PTPN11): c.184T> G (p.Tyr62Asp) single nucleotide variant Pathogenic rs121918460 GRCh38 Chromosome 12, 112450364: 112450364
3 46;XX;ins(5;6)(p13;p24p25)dn Translocation Pathogenic
4 46;XY;inv(6)(p22q13)dn inversion Pathogenic
5 46;XX;inv(7)(q21.2q34) inversion Likely pathogenic
6 46;XY;t(2;14)(p22;q24.3)dn Translocation Likely pathogenic
7 46;XX;ins(2;9)(q24.3;p22.1p24.3)dn Translocation Pathogenic

Expression for Patent Ductus Arteriosus 1

Search GEO for disease gene expression data for Patent Ductus Arteriosus 1.

Pathways for Patent Ductus Arteriosus 1

Pathways related to Patent Ductus Arteriosus 1 according to KEGG:

37
# Name Kegg Source Accession
1 Vascular smooth muscle contraction hsa04270

Pathways related to Patent Ductus Arteriosus 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.46 GATA4 GATA6 PTPN11
2 10.3 GATA4 NPPB

GO Terms for Patent Ductus Arteriosus 1

Biological processes related to Patent Ductus Arteriosus 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.62 GATA4 GATA6 NKX2-6 PTPN11
2 anatomical structure formation involved in morphogenesis GO:0048646 9.46 GATA4 GATA6
3 retina layer formation GO:0010842 9.43 TFAP2A TFAP2B
4 cell development GO:0048468 9.43 GATA4 GATA6 GDF1
5 positive regulation of urine volume GO:0035810 9.4 NPPB TFAP2B
6 endocardial cushion development GO:0003197 9.37 CRELD1 GATA4
7 intestinal epithelial cell differentiation GO:0060575 9.16 GATA4 GATA6
8 positive regulation of cardioblast differentiation GO:0051891 8.96 GATA4 GATA6
9 digestive tract development GO:0048565 8.8 GATA4 GATA6 NKX2-6

Molecular functions related to Patent Ductus Arteriosus 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II transcription factor activity, sequence-specific DNA binding GO:0000981 9.7 GATA4 GATA6 NKX2-6 PRDM6 TFAP2A TFAP2B
2 enhancer sequence-specific DNA binding GO:0001158 9.26 GATA4 TFAP2B
3 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.26 GATA4 GATA6 TFAP2A TFAP2B
4 sequence-specific DNA binding GO:0043565 9.1 GATA4 GATA6 NKX2-6 TFAP2A TFAP2B ZNF213

Sources for Patent Ductus Arteriosus 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....